NVS

Business Context and Reporting Period

Company: Novartis AG
Filing Type: Form 20-F (Annual Report)
Reporting Period: Fiscal year ended December 31, 2001
Accounting Standards: International Accounting Standards (IAS) with reconciliation to US GAAP.
Business Overview: Novartis is a global leader in pharmaceuticals, generics, consumer health, eyecare (CIBA Vision), and animal health. The company operates in over 140 countries with approximately 71,000 employees. In 2001, the company completed the spin-off of its Agribusiness sector (Syngenta) in late 2000, which is reported as a discontinued operation.

Key Financial Metrics (2001)

Note: USD figures are translated at the year-end rate of CHF 1.68 = $1.00.

Material Changes vs. Prior Period (2000)

• Sales Growth: Sales from continuing activities increased 10% in CHF (14% in local currencies) to CHF 32.0 billion. Growth was driven by an 8% volume increase and 2% price increase, partially offset by a 4% unfavorable currency effect (stronger Swiss Franc).
• Profitability: Operating income increased 8% to CHF 7.3 billion. Operating margin decreased slightly to 22.7% from 23.1% due to higher marketing and distribution expenses (up 16%) associated with new product launches.
• Net Income: Increased 8% to CHF 7.0 billion. Income from associated companies rose 43% primarily due to the new investment in Roche Holding Ltd.
• Segment Performance:
  • Pharmaceuticals: Sales up 11% (CHF 20.2B). Diovan/Co-Diovan became the best-selling product. Glivec/Gleevec launched successfully.
  • Generics: Sales up 23% (CHF 2.4B) driven by acquisitions (Apothecon, BASF) and generic fluoxetine launch.
  • CIBA Vision: Sales up 28% (CHF 1.8B) driven by the Wesley Jessen acquisition and new lens products.
  • Animal Health: Sales declined 11% (CHF 0.96B) due to US inventory reductions and foot-and-mouth disease impacts in Europe.
• Acquisitions: Acquired 21.3% of Roche Holding Ltd (CHF 5.2B) and various generics businesses (Apothecon, BASF, Labinca, Lagap).

Guidance, Outlook, Risks, and Unusual Items

• Outlook: Management expects 2002 capital expenditures to be approximately the same as 2001 (CHF 1.4B), funded by internal resources. The company anticipates continued pressure on pricing and operating results due to government reforms and generic competition.
• Patent Expirations: Significant risk from patent expirations for key products including Neoral (cyclosporin), Aredia (pamidronate), Sandostatin (octreotide), and Voltaren (diclofenac). Generic versions of Aredia entered the US market in late 2001.
• Regulatory Risks: Potential delays in FDA approvals (e.g., Zelnorm/tegaserod received a non-approvable letter; Xolair/omalizumab requires additional data). Price controls in the US (Medicare reform) and Europe remain a concern.
• Unusual Items:
  • Impairment: CHF 216 million charge for impairment of pitavastatin marketing rights.
  • Restructuring: CHF 21 million charge for closure of a UK Consumer Health facility.
  • Divestiture: Announced intention to divest the Health and Functional Food portion of Consumer Health (excluding Gerber) by end of 2002.

Investor Verification Checklist

• Patent Cliff Impact: Verify the actual sales erosion of Neoral, Aredia, and Sandostatin in 2002 as generic competition intensifies.
• Roche Investment: Monitor the equity method accounting impact of the 21.3% Roche stake and potential strategic developments.
• Regulatory Approvals: Track FDA/EMEA decisions for key pipeline drugs: Zelnorm (tegaserod), Xolair (omalizumab), and Certican (everolimus).
• Consumer Health Divestiture: Confirm the timeline and financial terms of the planned divestiture of Health and Functional Foods.
• Currency Exposure: Assess the impact of the strong Swiss Franc on reported earnings, given 45% of sales are in USD and 23% in Euro.
• US GAAP Reconciliation: Note the significant difference in Net Income between IAS (CHF 7.0B) and US GAAP (CHF 4.7B) due to purchase accounting adjustments and in-process R&D write-offs.